These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 11911412)

  • 1. Multiple bone lesions after allogeneic bone marrow transplantation in a patient with relapsed adult acute lymphoblastic leukemia: minimal residual disease analysis may predict extramedullary relapse.
    Nomura K; Okamoto T; Nakao M; Ueda K; Akano Y; Fujita Y; Kobayashi M; Yokota S; Horiike S; Nishida K; Kusuzaki K; Taniwaki M
    Leuk Lymphoma; 2001; 42(6):1305-8. PubMed ID: 11911412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
    Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
    Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minimal residual disease status as a predictor of relapse after allogeneic bone marrow transplantation for children with acute lymphoblastic leukaemia.
    Knechtli CJ; Goulden NJ; Hancock JP; Harris EL; Garland RJ; Jones CG; Grandage VL; Rowbottom AW; Green AF; Clarke E; Lankester AW; Potter MN; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
    Br J Haematol; 1998 Aug; 102(3):860-71. PubMed ID: 9722317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Samuel S; Kapelushnik J; Brautbar C; Or R
    Blood; 1996 Mar; 87(6):2195-204. PubMed ID: 8630379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Polymerase chain reaction-based detection of minimal residual disease in acute lymphoblastic leukemia predicts relapse after allogeneic BMT.
    Radich J; Ladne P; Gooley T
    Biol Blood Marrow Transplant; 1995 Nov; 1(1):24-31. PubMed ID: 9118286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsed acute lymphoblastic leukemia: similar outcomes for autologous and allogeneic marrow transplantation in selected children.
    Parsons SK; Castellino SM; Lehmann LE; Eickhoff CE; Tarbell NJ; Sallan SE; Weinstein HJ; Billett AL
    Bone Marrow Transplant; 1996 May; 17(5):763-8. PubMed ID: 8733695
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.
    Knechtli CJ; Goulden NJ; Hancock JP; Grandage VL; Harris EL; Garland RJ; Jones CG; Rowbottom AW; Hunt LP; Green AF; Clarke E; Lankester AW; Cornish JM; Pamphilon DH; Steward CG; Oakhill A
    Blood; 1998 Dec; 92(11):4072-9. PubMed ID: 9834212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
    Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
    Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful prevention of hematological relapse for a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia after allogeneic bone marrow transplantation by donor leukocyte infusion.
    Yazaki M; Andoh M; Ito T; Ohno T; Wada Y
    Bone Marrow Transplant; 1997 Feb; 19(4):393-4. PubMed ID: 9051252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of minimal residual disease in Philadelphia chromosome positive acute lymphoblastic leukemia: rationale for bone marrow transplantation from the polymerase chain reaction point of view.
    Miyamura K; Takeo T; Kataoka T; Tahara T; Tanimoto M; Saito H
    Leuk Lymphoma; 1993 Oct; 11(3-4):181-9. PubMed ID: 8260893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
    Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
    Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
    Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
    Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated extramedullary relapse in children with acute lymphoblastic leukemia: a comparison between treatment results of chemotherapy and bone marrow transplantation. BFM Relapse Study Group.
    Borgmann A; Hartmann R; Schmid H; Klingebiel T; Ebell W; Göbel U; Peters C; Gadner H; Henze G
    Bone Marrow Transplant; 1995 Apr; 15(4):515-21. PubMed ID: 7655375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic role of E2A-PBX1 expression detected by real-time quantitative reverse transcriptase polymerase chain reaction (RQ-PCR) in B cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation.
    Hong Y; Zhao X; Qin Y; Zhou S; Chang Y; Wang Y; Zhang X; Xu L; Huang X
    Ann Hematol; 2018 Sep; 97(9):1547-1554. PubMed ID: 29705861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation.
    Tajima K; Amakawa R; Uehira K; Matsumoto N; Shimizu T; Miyazaki Y; Fujimoto M; Kishimoto Y; Fukuhara S
    Int J Hematol; 2000 Apr; 71(3):290-3. PubMed ID: 10846838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extramedullary (bone) relapse 16 months after allo bmt in a 7-year-old girl treated for acute lymphoblastic leukaemia from the second year of life].
    Tomaszewska R; Madziara W; Janik-Moszant A; Sonta-Jakimczyk D; Bohosiewicz J
    Med Wieku Rozwoj; 2001; 5(3 Suppl 1):37-42. PubMed ID: 12004150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.